KL-1333M is under clinical development by Abliva and currently in Phase II for Mitochondrial Diseases. According to GlobalData, Phase II drugs for Mitochondrial Diseases have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KL-1333M’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KL-1333M overview

KL-1333M is under development for the treatment of mitochondrial myopathy such as MELAS syndrome (Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke), Kearns-Sayre syndrome, Pearson syndrome, myoclonic epilepsy with ragged red fibers (MERRF) syndrome and mitochondrial respiratory chain deficiencies. The therapeutic candidate is administered through the oral route. KL1333 is an NAD+ modulator.

Abliva overview

Abliva, formerly NeuroVive Pharmaceutical AB, is a pharmaceutical company. The company develops medicines to treat mitochondrial diseases. It is investigating KL1333, a NAD+ cellular levels modulator against MELAS (Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes) – MIDD (maternally inherited diabetes mellitus and deafness) and KSS (Kearns-Sayre Syndrome) – CPEO (Chronic Progressive External Ophthalmoplegia Syndrome). It is also evaluating NVP015 program for the treatment of Leber’s hereditary optic neuropathy (LHON); NV354 drug targeting Leigh syndrome; NeuroSTAT for the treatment of traumatic brain injury (TBI). The company works in partnership with Yungjin Pharm Co Ltd, Newcastle University, Hainan Sihuan Pharmaceutical Co Ltd, Children’s Hospital of Philadelphia, University College London, Oroboros Instruments and other companies. Abliva is headquartered in Lund, Scania, Sweden.

For a complete picture of KL-1333M’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.